Skip to main content
IC

Matthew Weston

Stock Analyst at UBS

(0.39)
# 3,953
Out of 4,829 analysts
3
Total ratings
n/a
Success rate
-6.07%
Average return
Main Sectors:
Healthcare
Top Industries:
Drug Manufacturers - General

Stocks Rated by Matthew Weston

Novartis AG
Feb 13, 2025
Downgrades: Neutral
Price Target: n/a
Current: $108.70
Upside: -
AstraZeneca
Feb 13, 2025
Upgrades: Buy
Price Target: n/a
Current: $67.57
Upside: -